Group items tagged

Global Dermatology (GOD) is bimonthly journal founded by Torello Lotti. It is an international peer reviewed journal strives to publish highest quality manuscripts pertaining to dermatology and address global issues affecting patient health and care. We look forward to receiving your contribution! GOD welcomes direct submissions of manuscripts from authors. You can submit your manuscript to: submissions@oatext.comalternatively to: editor.god@oatext.com

Stay at the forefront of dermatology innovation with MD Newsline, your trusted partner for advanced insights in skin health. Discover What's Inside: * Cutting-Edge Dermatology Research to stay informed. * Innovative Treatment Insights that elevate patient care. * Culturally Sensitive Resources to meet diverse needs. Why MD Newsline? Empowering healthcare professionals with reliable, expert-led content that transforms patient outcomes and advances the field of dermatology. Access Exclusive Skin Care Insights Today! Join a vibrant community committed to redefining skin health. Visit https://mdnewsline.com/ Your journey to revolutionizing dermatology starts now-explore MD Newsline!

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

Leo Pharma, one of the leaders in medical dermatology, has appointed Kasper Künzel as Interim Vice President and General Manager for its UK and Ireland business. Kasper is an established leader within Leo Pharma, having previously been Vice President, IPO Preparedness Office, at Leo Pharma in Denmark. Kasper brings over 17 years of pharmaceutical experience, previously taking on local and global leadership positions across Leo Pharma in functions including R&D, Finance and Commercial. Having first joined Leo Pharma in Denmark in a financial function, his previous roles include General Manager in South Korea, Vice President of Corporate Transformation, and Director of R&D Business Finance He commented: "I am delighted to join the Leo Pharma UK and Ireland team and continue to build on the company's strong heritage in these markets. The UK and Ireland team are committed to the Leo Pharma values as a leader in medical dermatology, and I'm looking forward to all we can achieve together this year.

By application, joint pain accounted for the largest market share in 2017 Based on application, the veterinary pain management market has been segmented into joint pain, postoperative pain, cancer, and other applications. Other applications include traumatic pain, abdominal pain, neuropathic pain, dermatological pain, and mastitis. In 2017, joint pain held the largest share of the veterinary pain management market. The dominant share of this application segment has been attributed to the growing pet population, rising prevalence of osteoarthritis and musculoskeletal disorders in animals, and the increasing population of obese and overweight pets.

If you have dry & aging skin then choose Dermaroller. At Dr. Nivedita Dadu's Dermatology Clinic we provide this treatment with the addition of rejuvenating serums like hyaluronic acid. This helps counter fine lines and provide hydration & suppleness to the facial skin. The derma roller can be used for treating both men and women. It has various benefits to the skin such as: 1. Cellulite Removal Treatment 2. Anti-Aging Treatment 3. Using Minoxidil 5% along with Dermaroller for effective Hair Fall Treatment 4. Skin Smoothing Treatment 5. Scar Removal Treatment 6. Stretch Mark Treatment

https://youtu.be/_OBH5XZ8ZL8 #darkspots #pigmentation #skintreatments #lasertreatmentindelhi #skinglow #skintreatment #new #howto #best #india #delhi #dermatology #dermatologist #skinspecialist #skincare #skintreatment #skinsolution

A healthy menstrual cycle ensures a women's well being and may vary from one woman to another. Menstruation issues and disruption in the ovulation cycle is directly linked to the condition of PCOD. This condition occurs due to hormonal disbalance and has many health implications. Immoderate growth of hair on the face and body, pimples, blackheads, and many more skin concerns are associated with PCOD. At our clinic, you can find an ideal cocktail of various dermatology treatments that can help you curb the damage to your skin like chemical peels, acne check peel, and others along with oral medications. Are you or someone you know is suffering from PCOD? If yes, then this video is something you should consider watching. https://youtu.be/D34sdAIYzOo #pcod #pcos #pcosawarness #skintreatments #lasertreatmentindelhi #skinglow #skintreatment #new #howto #best #india #delhi #dermatology #dermatologist #skinspecialist #skincare #skintreatment #skinsolution

Sixty-seven per cent of UK independent pharmacists say the pandemic has positively changed how patients view the clinical services offered by community pharmacy. The research - carried out with an independent panel of more than 100 community pharmacists - revealed that 35 per cent of them had increased their clinical services to fulfil patient demand during the pandemic. Seventeen per cent said they had expanded their private clinical services such as vaccinations and dermatology, with a further 17 per cent adding sexual health services such as emergency contraception and chlamydia screening in their services offer. Thirty per cent introduced NHS health checks and emergency supply NHS services during the pandemic.

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for a total of about £2.9 billion. Viatris said its move to divest some of its businesses is part of its long-term strategy to streamline focus on three core therapeutic areas - ophthalmology, gastroenterology and dermatology. The company has received an offer of about $2.17 billion (£1.78 billion) for almost all of its over-the-counter drug business from France-based Cooper Consumer Health. Viatris will retain rights for erectile dysfunction drug Viagra, nasal spray Dymista and select OTC drugs within certain markets. Separately, the drugmaker said it has agreed to sell its women's healthcare business to Spanish pharmaceutical company Insud Pharma, while its active pharmaceutical ingredients business in India will be sold to Iquest Enterprises. Both divestitures would result in about $1.2 billion (£987 million) in proceeds.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

Jonathan Burton will receive the 2022 RPS Charter Award for his outstanding work for the Society and the wider profession in promoting the interests of pharmacy. The award will be presented by the President at a future meeting of Fellows and Members to take place at the Society's Edinburgh office on 22nd March 2023. Jonathan's main role is as a practising, patient-facing pharmacist within the community in NHS Forth Valley where he uses his advanced practice skills and independent prescribing qualification to assess and treat acute ENT, dermatology, and respiratory conditions. He was one of the first community pharmacist prescribers in Scotland and has always been at the forefront of innovation and service development. Jonathan has demonstrated outstanding commitment and passion for the pharmacy profession throughout his career. He has excelled as a pharmacist in the Right Medicine Pharmacy group, on local and national committees, in advocacy for the pharmacy profession and as a local and national leader who is highly regarded as an exceptional role model for the profession.

Over the past two years, the Covid pandemic has resulted in a backlog of elective care within the NHS, with record numbers of patients on waiting lists across the UK. Despite efforts to catch up after the first wave, subsequent waves have put further strain on an already stretched NHS system. This has had a tremendous impact on many patients waiting for routine dermatology appointments and, while every effort has been made to see patients with suspected serious skin cancers within two weeks, this target is not always achieved. With rising waiting times, pharmacists are increasingly the first port of call for patients suffering with a broad range of skin problems. From acne and rosacea, eczema or psoriasis, to changing skin lesions or simple insect bites, pharmacists can give helpful advice, allowing some customers to find quick relief to their skin complaint in mild cases, while directing others to see their GP without delay. Below is some practical advice that pharmacists can give to their customers with commonly encountered skin complaints. Acne Acne is a common skin condition that not only affects teenagers but adults too. It is estimated that up to 40 per cent of women continue to suffer with acne into their adult years. Acne has been linked to an increased incidence of depression, anxiety and even suicidal ideation. Patients have reported feeling overlooked and often dismissed in their concerns by health care professionals. Unfortunately, these issues have been further compounded by delays in being seen and treated due to the ongoing Covid pandemic. Pharmacists are well placed to help acne patients choose the right skincare. This should consist of lightweight products, such as gel or milky cleansers, with moisturisers in serum, lotion or light cream preparations. Some acne suitable products are further labelled as non-comedogenic. Oil-based or occlusive preparations are best avoided. There are many good quality, non-comedogenic sun blocks suited

Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire. The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters. LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee wellbeing. This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people living with skin conditions, their families and society.

The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday, September 15. COMCO conducted an early morning raid on the company on Sept. 13, it said in a statement that did not name Novartis, which subsequently said in its own statement that it was the group under investigation. "The company allegedly attempted to protect its drug for the treatment of skin diseases against competing products by using one of its patents to initiate litigation proceedings," COMCO said in a statement. Novartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of dermatology treatments. "In connection with this investigation, COMCO representatives visited the company headquarters in Basel," it said.